Streetbeat News

Analyst Ratings

ANIP

Guggenheim analyst Vamil Divan maintains a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and raises the price target from $62 to $72.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:38 pm

FTCI

Piper Sandler analyst Kashy Harrison maintains a Neutral rating on FTC Solar (NASDAQ:FTCI) and lowers the price target from $3 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:37 pm

IPSC

Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Century Therapeutics (NASDAQ:IPSC) but lowers the price target from $14 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:36 pm

ARHS

Guggenheim analyst Steven Forbes maintains a Buy rating on Arhaus (NASDAQ:ARHS) and raises the price target from $12 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:34 pm

GDRX

Guggenheim analyst Sandy Draper maintains a Buy rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $8 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:33 pm

ATVI

A whale investor has taken a bearish stance on Activision Blizzard (NASDAQ:ATVI), with 72% of the spotted trades being bearish. The whales have been targeting a price range from $50.0 to $92.5 for Activision Blizzard over the last 3 months. Several experts have downgraded their action on ATVI to Hold or Neutral with price targets ranging from $90 to $95. The current price of ATVI is $91.44.

Portfolio Pulse from Benzinga Insights

August 10, 2023 | 7:32 pm

PFE

A significant amount of unusual options activity has been detected for Pfizer (NYSE:PFE), with a majority of investors taking a bullish stance. The trades have targeted a price range of $30.0 to $52.5 for Pfizer over the last 3 months. The current price of PFE is $35.82, with RSI indicators suggesting a neutral position. Several financial institutions have maintained or upgraded their ratings on Pfizer, with price targets ranging from $40 to $62.

Portfolio Pulse from Benzinga Insights

August 10, 2023 | 7:32 pm

AVDL

Piper Sandler analyst David Amsellem has maintained an Overweight rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raised the price target from $13 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:32 pm

ARHS

Piper Sandler analyst Peter Keith maintains an Overweight rating on Arhaus (NASDAQ:ARHS) and raises the price target from $13 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:30 pm

GCMG

Piper Sandler analyst Sumeet Mody maintains an Overweight rating on GCM Grosvenor (NASDAQ:GCMG) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:29 pm